藤黄酸在乳腺癌治疗中的研究进展  

Advances in the study of gambogic acid in the treatment of breast cancer

作　　者：达梦婷 陈道桢 杨蕊 宿晨 张瑾 沈国双[1] DA Mengting;CHEN Daozhen;YANG Rui;SU Chen;ZHANG Jin;SHEN Guoshuang(Breast Disease Diagnosis and Treatment Center,Affiliated Hospital of Qinghai University,Xining,Qinghai 810000,China;Office of the President,Haidong Second People's Hospital,Haidong,Qinghai 810600,China;Institute of Eugenics and Genetic Medicine,Wuxi Maternal and Child Health Center,Wuxi,Jiangsu 214002,China)

机构地区：[1]青海大学附属医院乳腺疾病诊疗中心,青海西宁810000 [2]海东市第二人民医院院长办公室,青海海东810600 [3]无锡妇幼保健院优生优育遗传医学研究所,江苏无锡214002

出　　处：《安徽医药》2024年第1期1-5,共5页Anhui Medical and Pharmaceutical Journal

基　　金：青海省自然科学基金面上项目(2022-ZJ-912)。

摘　　要：藤黄酸作为中药藤黄的主要生物活性成分,通过多种机制发挥抗肿瘤作用,包括诱导细胞凋亡、抑制肿瘤血管的生成和转移以及逆转肿瘤的多药耐药等;尤其是在乳腺癌治疗中可发挥多种抗肿瘤作用,有望成为乳腺癌的治疗药物。但藤黄酸自身存在缺陷,如水溶性差、半衰期短等,限制其临床应用。随着纳米载药制剂的不断发展,有望改善藤黄酸的不足,发挥藤黄酸强大的抗肿瘤作用。因此,综述近五年藤黄酸治疗乳腺癌的相关文献,以期为最大化藤黄酸抗乳腺癌奠定基础。Gambogic acid,as the main bioactive component of gambogic,exerts anti-tumor effects through various mechanisms,in⁃cluding induction of apoptosis,inhibition of tumor angiogenesis and metastasis,and reversal of tumor multidrug resistance.In particu⁃lar,it can exert a variety of anti-tumour effects in the treatment of breast cancer and is expected to become a breast cancer treatment drug.However,gambogic has its own defects,such as poor water solubility and short half-life,which limit its clinical application.With the continuous development of nano-loaded drug formulations,it is expected to improve the shortcomings of gambogic acid and bring in⁃to play its powerful anti-tumour effects.Therefore,we reviewed the literature related to gambogic acid in breast cancer treatment in the past five years,in order to lay the foundation for maximizing gambogic acid against breast cancer.

关 键 词：藤黄属 乳腺癌 抗肿瘤作用 纳米制剂 药物载体 综述 

分 类 号：R737.9[医药卫生—肿瘤]